The proposed acquisition combines PET manufacturing capacity and diagnostic rights; its real strategic test is whether time-critical delivery becomes a reusable moat.
On October 5, GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences for $945 million in cash. The deal has not closed. GE expects completion in the first half of 2027, subject to conditions including regulatory approvals. The target brings 15 U.S. contract-manufacturing sites, 21 cyclotrons, a theranostics-focused CDMO facility, and U.S. rights to the Phase III FAPI-74 diagnostic PET tracer. [GE HealthCare release]
The capital-markets question is not simply what a new radiotracer is worth. It is what a buyer should pay for the ability to manufacture and deliver short-lived tracers close enough to patients, reliably enough, to turn a promising molecule into an accessible product. Fluorine-18 PET products have a roughly 110-minute half-life. Geography and scheduling therefore become commercial variables, not merely back-office logistics. [GE HealthCare release]
Sources / 来源
GE HealthCare拟收购SOFIE的美国PET生产网络与FAPI-74权利。真正的定价问题是：短半衰期药物的交付能力，何时成为战略资产？
10月5日，GE HealthCare宣布同意以9.45亿美元现金收购美国PET放射性药物代工网络SOFIE Biosciences。交易尚未交割，预计在2027年上半年、满足监管等条件后完成。这不是一笔只看候选药物的交易：买方同时看中了15个美国代工站点、21台回旋加速器、一个面向诊疗一体化的研发生产设施，以及一项已进入三期的FAPI-74美国诊断权利。[GE HealthCare公告]
我的研究判断是：在放射性药物行业，价值的一部分不是分子的专利，而是把分子准时送到患者面前的能力。氟-18标记PET示踪剂约110分钟的半衰期，让供应链的距离和排程直接进入产品可及性。这使区域化生产网络可能成为商业化瓶颈，也可能成为战略买方愿意收购的资产。[GE HealthCare公告]